CORRECTION article

Front. Immunol.

Sec. Multiple Sclerosis and Neuroimmunology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1652299

Correction: The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm

Provisionally accepted
Robert HoffroggeRobert Hoffrogge1Anna KarachunskayaAnna Karachunskaya1Neele HeitmannNeele Heitmann1Steffen HaupeltshoferSteffen Haupeltshofer2Xiomara PedreiturriaXiomara Pedreiturria1Katharina KlösterKatharina Klöster1Verian BaderVerian Bader3Konstanze WinklhoferKonstanze Winklhofer3Michael HamacherMichael Hamacher4Bert KleblBert Klebl5Ralf Karl GoldRalf Karl Gold1Klaus DinkelKlaus Dinkel6Ingo KleiterIngo Kleiter7Simon FaissnerSimon Faissner1*
  • 1Department of Neurology, St. Josef-Hospital, Bochum, Germany
  • 2Translational Neurology Group, Department of Clinical Science, Lund University, 22184 Lund, Sweden
  • 3Molecular Cell Biology, Ruhr-University, Bochum, Germany
  • 4Affectis Pharmaceuticals AG, Dortmund, Germany
  • 5KHAN Technology Transfer Fund I GmbH & Co KG, Dortmund, Germany
  • 6Lead Discovery Center GmbH, Dortmund, Germany
  • 7Behandlungszentrum Kempfenhausen fur Multiple Sklerose Kranke gemeinnutzige GmbH, Berg, Germany

This article is a correction to:

  1. The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm

    1. Read original article

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Correction: The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm Name of all authors as they appear in the published original article (correct version) Robert Hoffrogge1, Anna Karachunskaya1, Neele Heitmann1, Steffen Haupeltshofer2, Xiomara Pedreiturria1, Katharina Klöster1, Verian Bader3, Konstanze F. Winklhofer3, Michael Hamacher4, Bert Klebl5, Ralf Gold1, Klaus Dinkel6, Ingo Kleiter1,7, Simon Faissner1* Affiliations of all authors as they appear in the published original version of the article (correct version) 1Department of Neurology, St. Josef-Hospital, Bochum, Germany 2Translational Neurology Group, Department of Clinical Science, Lund University, 22184, Lund, Sweden 3Molecular Cell Biology, Ruhr-University, Bochum, Germany 4Affectis Pharmaceuticals AG, Dortmund, Germany 5KHAN Technology Transfer Fund I GmbH & Co KG, Dortmund, Germany 6Lead Discovery Center GmbH, Dortmund, Germany 7Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Berg, Germany * Correspondence: simon.faissner@rub.de Keywords: same as original article Correction on: Hoffrogge Robert , Karachunskaya Anna , Heitmann Neele , Pedreiturria Xiomara , Klöster Katharina , Bader Verian , Winklhofer Konstanze F. , Hamacher Michael , Klebl Bert , Gold Ralf , Dinkel Klaus , Kleiter Ingo , Faissner Simon TITLE = The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm JOURNAL=Frontiers in Immunology VOLUME=Volume 16 - 2025 YEAR=2025 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1554999 DOI=10.3389/fimmu.2025.1554999 ISSN=1664-3224 Error in author list Please also check that the initials used in the author contributions section or elsewhere in the article are correct. In the published article, there was an error in the author list, and author Steffen Haupeltshofer was erroneously excluded. The corrected author list appears below. Robert Hoffrogge1, Anna Karachunskaya1, Neele Heitmann1, Steffen Haupeltshofer2, Xiomara Pedreiturria1, Katharina Klöster1, Verian Bader3, Konstanze F. Winklhofer3, Michael Hamacher4, Bert Klebl5, Ralf Gold1, Klaus Dinkel6, Ingo Kleiter1,7, Simon Faissner1* The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. The following sentence should be added to the authors contribution section: ´SH: Writing – original draft, Writing – review & editing, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization.´

Keywords: P2X7R, Progressive multiple sclerosis, Microglia, Neuroinflammation, Neuroprotection

Received: 23 Jun 2025; Accepted: 09 Jul 2025.

Copyright: © 2025 Hoffrogge, Karachunskaya, Heitmann, Haupeltshofer, Pedreiturria, Klöster, Bader, Winklhofer, Hamacher, Klebl, Gold, Dinkel, Kleiter and Faissner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Simon Faissner, Department of Neurology, St. Josef-Hospital, Bochum, Germany

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material